Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Find studies

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Digital Isolation and Dementia Risk in Older Adults: Longitudinal Cohort Study

✓ Peer-reviewed alzhub usefulness score 54 out of 100. Journal of Medical Internet Research 2025-01-12

The moderate to high isolation group demonstrated a significantly elevated risk of dementia compared with the low isolation group. 5 key findings →

Design: cohort study Participants: 8,189 Evidence: moderate

We identify three distinct profiles: active healthy sleepers (AHS; 64.0%), fragmented poor sleepers (FPS; 14.1%), and long and frequent nappers (LFN; 21.9%). 3 key findings →

Design: cohort study Evidence: moderate

An Ensemble Learning Artificial Intelligence Model for Alzheimer's Disease Detection Using OCT

✓ Peer-reviewed alzhub usefulness score 54 out of 100. Ophthalmology Science 2026-01-10

For detecting AD-dementia, the ensemble model achieved the area under the receiver operating characteristic curve (AUROC) of 0.943 (95% confidence interval, 0.906-0.980), 0.786 (95% confidence interval, 0.673-0.899), and 0.795 (95% confidence interval, 0.716-0.874) in the internal validation, External-1, and External-2, respectively. 4 key findings →

Design: case-control study Participants: 190 Evidence: moderate

To develop a simplified smell test for identifying patients with Parkinson's disease (PD), we reevaluated the Sniffin'-Sticks-Identification-Test (SST-ID) and University-of-Pennsylvania-Smell-Identification-Test (UPSIT), using three case-control studies. 1 key finding →

Design: case-control study Participants: 301 Evidence: moderate

In response to correspondence from Cognivue, Inc. regarding our publication (Jannati et al., 2025), we clarify that our analysis employed a rigorous paired-sample design using the same 930 participants from the Bio-Hermes-001 study for both the Digital Clock and Recall® (DCR) and Cognivue Clarity® assessments. 3 key findings →

Participants: 930 Evidence: low

From an ethical perspective, important benefits of embodied AI applications in mental health include new modes of treatment, opportunities to engage hard-to-reach populations, better patient response, and freeing up time for physicians. 2 key findings →

Evidence: low

The ability of the model to discriminate incident cases of dementia implies that it can be a worthwhile tool to screen patients for trial recruitment and patient management. 1 key finding →

Participants: 121,907 Evidence: moderate

We demonstrated that it was both feasible and acceptable to set up these sensors in the community and unobtrusively collect data. 3 key findings →

Design: cross-sectional Participants: 59 Evidence: low

Explainable AI-based Alzheimer's prediction and management using multimodal data

✓ Peer-reviewed alzhub usefulness score 53 out of 100. PloS one 2023-11-16

According to the World Health Organization (WHO), dementia is the seventh leading reason of death among all illnesses and one of the leading causes of disability among the world's elderly people. 1 key finding →

Evidence: low

Converging evidence suggests that the accumulation of cerebral amyloid beta-protein (Abeta) in Alzheimer's disease (AD) reflects an imbalance between the production and degradation of this self-aggregating peptide. 3 key findings →

Evidence: low

The increasing prevalence of Alzheimer’s disease and related dementias (ADRD) places growing strains on family caregivers. 1 key finding →

Design: systematic review Participants: 24 Evidence: high

Both ML short forms showed high internal consistency (α = 0.96 for ML-WHODAS-16 and 0.93 for ML-WHODAS-10) and excellent concurrent validity with the full WHODAS-32 (r = 0.98 for both). 5 key findings →

Design: longitudinal study Participants: 31,952 Evidence: moderate

The best-performing model achieved an area under the curve of 0.86 (95% confidence interval [CI]: 0.84-0.87), with sensitivity of 73.3% (95% CI: 72.3-74.2) and specificity of 87.5% (95% CI: 86.7-88.2). 5 key findings →

Design: case-control study Participants: 8,195 Evidence: moderate

This study included 33,355 patients in the training, 14,294 in the internal validation, and 6711 in the external validation sets. 5 key findings →

Design: cohort study Participants: 33,355 Evidence: moderate

When validated with subjects diagnosed using an official test, the model achieves COVID-19 sensitivity of 98.5% with a specificity of 94.2% (AUC: 0.97). 5 key findings →

Participants: 19 Evidence: low

Diffusion tensor imaging (DTI) based assessment of white matter fiber tract integrity can support the diagnosis of Alzheimer's disease (AD). 4 key findings →

Participants: 137 Evidence: low

The clinical prediction model can play a beneficial role in decision-making for preventative measures for patients at risk of developing a delirium. 3 key findings →

Participants: 207 Evidence: low

The machine learning model developed in this study demonstrated strong classification performance in detecting and differentiating depression, anxiety, and apathy. 3 key findings →

Design: cross-sectional Evidence: low

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed